Maviret (glecaprevir/pibrentasvir) approved by Health Canada for paediatric patients with chronic hepatitis C


22 June 2022 - This approval is supported by 98.4 per cent cure rate across this group of patients who received the approved paediatric granule formulation.

AbbVie announced today that Health Canada has approved a change in the marketing authorisation for Maviret (glecaprevir/pibrentasvir) to include its use for the treatment in paediatric patients 3 to 12 years old, weighing at least 12kg to less than 45kg.

Read AbbVie press release

Michael Wonder

Posted by:

Michael Wonder